Our thanks to all of these top-tier organizations for helping make this event possible. For more information on how you can sponsor this or other ChinaBio events, please contact Jean Meng.
The Shunde District is situated in the central part of the Pearl River Delta (PRD), and was established during the Ming Dynasty (1452). Shunde currently has a resident population of 2.51 million and has ranked as one of the most affluent counties in Southern China since 2000. As the cradle of Cantonese song and opera, Shunde cultivates a wide variety of local culture. In 2014, Shunde was also identified by UNESCO as a “City of Gastronomy” due to its excellent food, including special dishes unique to the region. Shunde is also an important transportation and economic hub in the Pearl River Delta, connecting Shenzhen, Guangzhou, Hong Kong, Zhuhai and Macau within a two-hour traffic circle. In order to promote its transformation from an industrial base to an innovation base, the Shunde Government is building the Shunde Hi-tech Industrial Park Promotion Zone, including the “Sino-European Service Center” which will be the home to Qianju Bio Park and the VIC-ChinaBio Life Science Accelerator. Other platforms attracting life science companies to Shunde include a 1000 mu (165 acres) park for biotechnical innovation, industrial development and manufacturing, further enhancing the core competitiveness of the region.
Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$15 billion assets and has invested in approximately 300 private companies across a wide range of therapeutic categories and stages of development, over 100 of which have been either listed or acquired. OrbiMed’s investment team includes over 80 experienced professionals with backgrounds in ilfe science, medicine, finance and law. OrbiMed Asia, with offices in Shanghai and Mumbai, has established one of the first pan-Asia healthcare-dedicated PE/VC funds. With over USD$500 million under management, it has made investments in 31 companies. OrbiMed’s public equity funds have invested approximately USD$1 billion in public healthcare companies listed in Asia.
Guangdong Qianju Biotechnology Co., Ltd. is the operator of Guangdong (Shunde) International Life & Health Innovation Startup Demonstration Zone, which provides a full chain of professional services including technology, finance, personnel, detection, evaluation and trade, for life and health innovation technology teams from home and abroad, with the goal to build an international life and health property transaction platform and lead Chinese life and health industry to global market. We will start up in Sino-European Services Center (SESC) focusing on such constructions as the International Life & Health Industry Incubation Base, the “Thousand Talents Program” Life & Health Joint Research Institute, the Life & Health Industry Investment and Financing Platform, and the International Life & Health Property Transaction and Technology Transfer Center, etc. In addition, we will hold a series of international life & health industry development and investment summits, and organize international life & health industry trade fairs to connect project resource with global market.
ChinaBio® Group has joined forces with VIC Technology Venture Development to form the VIC-ChinaBio® Life Science Incubator in Shunde, China. The VIC-ChinaBio® Incubator will leverage VIC's 13 years of experience creating life science companies around novel IP licensed from leading universities in the US with ChinaBio's deep experience helping over 30 companies find VC funding, strategic partners and government support in China. VIC-ChinaBio® will provide a wide range of resources to their resident companies:
- 3000 m2 of quality office space in the Sino-European Services Center
- 1000 m2 of shared and dedicated lab space focused on biologics, medical devices and diagnostics development
- VC funding / strategic partnerships
- Matching government funding
- Assistance with corporate formation, grant applications, logistics, etc.
- A wide range of support for rent, housing, salaries, key staff, etc.
The VIC-ChinaBio® Incubator will bring VIC's portfolio companies to China, as well as existing or early stage companies with a strategic focus on China. The Incubator will focus on companies with novel IP in drugs (especially biologics), medical devices, and diagnostics.
BayHelix is an organization of leaders of Chinese origin in the global life sciences and healthcare community. Their mission is to help shape the growth of the life science and healthcare industry around the Pacific Rim and beyond, foster and create business opportunities, supply and nurture the leaders for the community, and network and share information and experience. BayHelix is a non-profit organization and its membership is by invitation only.
BioCentury Publications, Inc., www.biocentury.com provides essential biopharma industry intelligence from five offices in the U.S. and Europe. For more than 18 years, a global audience of biotech and pharmaceutical executives and investors has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia. BioCentury's titles include the flagship BioCentury, the Bernstein Report on BioBusiness; SciBX: Science-Business eXchange, a translational science joint publishing venture with Nature Publishing Group; and BioCentury Extra, online daily news covering breaking developments BioCentury also markets its BCIQ: BioCentury Online Intelligence, an online business intelligence resource. In September 2010, the company launched BioCentury This Week, the first weekly biotech public affairs TV program to be broadcast in major U.S. television markets, a partnership with the Gannett-owned CBS affiliate W*USA Channel 9 in Washington, D.C.
For more sponsorship information , please contact:
Tel: +86 21 5137 0751 ext 12
From USA: +1 858 926 4566 ext 12